Company intelligence / Profile preview

Limbix

San Francisco, California, United Statesblog.limbix.com ↗

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

SparkRx by Limbix demonstrated feasibility and acceptability in pilot studies for adolescent depression. A larger randomized controlled trial was planned with Duke Clinical Research Institute and Stanford University to support FDA clearance. During the COVID public health emergency, SparkRx was made available without prescription under FDA enforcement discretion. No final pivotal data or commercial launch reported prior to acquisition.

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapy (Digital therapeutic)Device (Mobile app)Cognitive behavioral therapy-based digital intervention
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

SparkRx

Commercial

Indications: Depression

Partnerships

Duke Clinical Research InstituteStanford University

Beyond the preview

Go deeper on Limbix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Limbix.

Explore the full profile